

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

\_\_\_\_\_  
Type or print name of person signing certification

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: BEAVERS Lisa Selsam  
For: HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION  
AND THERAPEUTIC USES  
Docket No.: X16648

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/Dan L. Wood/  
Dan L. Wood  
Attorney for Applicants  
Registration No. 48,613  
Phone: 317-277-3366

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
August 23, 2006

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16648	Serial No
	First Applicant Lisa Selsam Beavers	
	Application Date US Nat'l Entry (if applicable) «NationalEntryDate»	Group Art Unit

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US			
	AB	US			
	AC	US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	FR 1 494 630	09-08-1967	S. Sandoz	Page 1, column 2, paragraph 2	
	BB	UK 840 358	07-06-1960	The British Drug Houses Limited	Example 17	
	BC	EP 0 375 297	06-24-1990	Eli Lilly and Company	Page 1, lines 10, 11 Page 1 Formula I Page 10, line 19	
	BD	WO 02/076925	10-03-2002	Eli Lilly and Company	Claims; examples 130-133, 136, 144, 209- 216, 229- 235, 242, 243, 25 1-255, 26	
	BE	WO 03/064411	08-07-2003	Novo Nordisk A/S; 1-22 Boehringer Ingelheim International GmbH)	Claims; page 60 - page 61; example 28	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Examiner Signature	/Erich Leeser/	Date Considered	11/25/2009
-----------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)	Atty. Docket No. X-16648	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Lisa Selsam Beavers	
	Application Date US Nat'l Entry (if applicable) «NationalEntryDate»	Group Art Unit

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	Fujimura et al., "Syntheses and pharmacological action of Tetralin derivatives," <i>Yakugaku Zasshi – Journal of the Pharmaceutical Society of Japan</i> , no. 74, pp 954-956, 1954.	
	CB		
	CC		
	CD		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Examiner Signature	/Erich Leeser/	Date Considered	11/25/2009
-----------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.